Free Trial
NASDAQ:NTHI

Neonc Technologies Q3 2025 Earnings Report

Neonc Technologies logo
$4.54 -0.21 (-4.38%)
As of 11:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Neonc Technologies EPS Results

Actual EPS
-$0.45
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Neonc Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neonc Technologies Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Neonc Technologies' next earnings date is estimated for Friday, August 14, 2026, based on past reporting schedules.

Conference Call Resources

Neonc Technologies Earnings Headlines

From Nokia to NeOnc: The Stocks Dominating Screens as Volume Spikes
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
The Next Great AI Revolution May Be Drug Delivery
See More Neonc Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neonc Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neonc Technologies and other key companies, straight to your email.

About Neonc Technologies

Neonc Technologies (NASDAQ:NTHI) develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

View Neonc Technologies Profile